Utility estimates for patients with Type 2 diabetes mellitus after experiencing a myocardial infarction or stroke: a systematic review

References

• Papaioannou D, Brazier J, Paisley S. Systematic searching and selection of health state utility values from the literature. Value Health 2013;16:686-95
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013. Available from: www.nice.org.uk/media/D45/1E/GuideToMethodsTechnologyAppraisal2013.pdf [Last accessed 11 March 2014]
   Google Scholar
• Pharmaceutical Benefits Advisory Committee (PBAC). Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.4). Available from: www.pbac.pbs.gov.au/ [Last accessed 20 March 2014]
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the economic evaluation of health technologies: Canada. 2006. Available from: www.cadth.ca/media/pdf/186_EconomicGuidelines_e.pdf [Last accessed 11 March 2014]
   Google Scholar
• González EL, Johansson S, Wallander MA, Rodríguez LA. Trends in the prevalence and incidence of diabetes in the UK: 1996-2005. J Epidemiol Community Health 2009;63:332-6
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a randomised controlled trial. Lancet 2005;366:1279-89
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd edition. Oxford University Press; Oxford, UK: 2005
   Google Scholar
• Brennan VK, Colosia AD, Copley-Merriman C, et al. Incremental costs associated with myocardial infarction and stroke in patients with type 2 diabetes mellitus: an overview for economic modeling. J Med Econ 2014;17:469-80
   PubMedGoogle Scholar
• Glasziou P, Alexander J, Beller E, Clarke P. Which health-related quality of life score? A comparison of alternative utility measures in patients with type 2 diabetes in the ADVANCE trial. Health Qual Life Outcomes 2007;5:21
   PubMed Web of Science ®Google Scholar
• O’Reilly DJ, Xie F, Pullenayegum E, et al. Estimation of the impact of diabetes-related complications on health utilities for patients with type 2 diabetes in Ontario, Canada. Qual Life Res 2011;20:939-43
   PubMed Web of Science ®Google Scholar
• Maddigan SL, Feeny DH, Majumdar SR, et al. Health Utilities Index mark 3 demonstrated construct validity in a population-based sample with type 2 diabetes. J Clin Epidemiol 2006;59:472-7
   PubMed Web of Science ®Google Scholar
• Hunger M, Schunk M, Meisinger C, et al. Estimation of the relationship between body mass index and EQ-5D health utilities in individuals with type 2 diabetes: evidence from the population-based KORA studies. JDiabetes Complications 2012;26:413-18
   PubMed Web of Science ®Google Scholar
• Kontodimopoulos N, Pappa E, Chadjiapostolou Z, et al. Comparing the sensitivity of EQ-5D, SF-6D and 15D utilities to the specific effect of diabetic complications. Eur J Health Econ 2012;13:111-20
   PubMed Web of Science ®Google Scholar
• Lee WJ, Song KH, Noh JH, et al. Health-related quality of life using the EuroQol 5D questionnaire in Korean patients with type 2 diabetes. J Korean Med Sci 2012;27:255-60
   PubMed Web of Science ®Google Scholar
• Wermeling PR, Gorter KJ, van Stel HF, Rutten GE. Both cardiovascular and non-cardiovascular comorbidity are related to health status in well-controlled type 2 diabetes patients: a cross-sectional analysis. Cardiovasc Diabetol 2012;11:121
   PubMed Web of Science ®Google Scholar
• Adibe MO, Aguwa CN. Sensitivity and responsiveness of Health Utility Indices (HUI2 and HUI3) among type 2 diabetes patients. Trop J Pharm Res 2013;12:835-42
   Web of Science ®Google Scholar
• Solli O, Stavem K, Kristiansen IS. Health-related quality of life in diabetes: the associations of complications with EQ-5D scores. Health Qual Life Outcomes 2010;8:18
   PubMed Web of Science ®Google Scholar
• Quah JHM, Luo N, Ng WY, et al. Health-related quality of life is associated with diabetic complications, but not with short-term diabetic control in primary care. Ann Acad Med Singapore 2011;40:276-86
   PubMed Web of Science ®Google Scholar
• Kiadaliri AA, Gerdtham UG, Eliasson B, et al. Health utilities of type 2 diabetes-related complications: a cross-sectional study in Sweden. Int J Environ Res Public Health 2014;11:4939-52
   PubMed Web of Science ®Google Scholar
• Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340-9
   PubMed Web of Science ®Google Scholar
• Alva M, Gray A, Mihaylova B, Clarke P. The effect of diabetes complications on health-related quality of life: the importance of longitudinal data to address patient heterogeneity. Health Econ 2014;23:487-500
   PubMed Web of Science ®Google Scholar
• Coffey JT, Brandle M, Zhou H, et al. Valuing health-related quality of life in diabetes. Diabetes Care 2002;25:2238-43
   PubMed Web of Science ®Google Scholar
• Zhang P, Brown MB, Bilik D, et al. Health utility scores for people with type 2 diabetes in U.S. managed care health plans. Diabetes Care 2012;35:2250-6
   PubMed Web of Science ®Google Scholar
• Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005;14:217-30
   PubMed Web of Science ®Google Scholar
• Cameron C, Coyle D, Ur E, Klarenbach S. Cost-effectiveness of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulin. CMAJ 2010;182:28-34
   PubMed Web of Science ®Google Scholar
• Kahn R, Alperin P, Eddy D, et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 2010;375:1365-74
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC) Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002;287:2542-51
   PubMed Web of Science ®Google Scholar
• Laiteerapong N, John PM, Meltzer DO, Huang ES. Impact of delaying blood pressure control in patients with type 2 diabetes: results of a decision analysis. J Gen Intern Med 2012;27:640-6
   PubMed Web of Science ®Google Scholar
• Yu J, Shah BM, Ip EJ, Chan J. A. Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California. J Manag Care Pharm 2013;19:102-14
   PubMed Web of Science ®Google Scholar
• Pollock RF, Valentine WJ, Pilgaard T, Nishimura H. The cost effectiveness of rapid-acting insulin aspart compared with human insulin in type 2 diabetes patients: an analysis from the Japanese third-party payer perspective. J Med Econ 2011;14:36-46
   PubMedGoogle Scholar
• Brändle M, Azoulay M, Greiner RA. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland. Int J Clin Pharmacol Ther 2011;49:217-30
   PubMed Web of Science ®Google Scholar
• Valentine WJ, Bottomley JM, Palmer AJ, et al. PROactive Study Group. PROactive 06: cost-effectiveness of pioglitazone in type 2 diabetes in the UK. Diabet Med 2007;24:982-1002
   PubMed Web of Science ®Google Scholar
• Woehl A, Evans M, Tetlow AP, McEwan P. Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom (structured abstract). Cardiovasc Diabetol 2008;7:24
   PubMed Web of Science ®Google Scholar
• Clarke PM, Gray AM, Briggs A, et al. UK Prospective Diabetes Study (UKDPS) Group. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS No 68). Diabetologia 2004;47:1747-59
   PubMed Web of Science ®Google Scholar
• Clarke PM, Gray AM, Briggs A, et al. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 2005;48:868-77
   PubMed Web of Science ®Google Scholar
• Ramsey SD, Clarke LD, Roberts CS, et al. An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes. Pharmacoeconomics 2008;26:329-39
   PubMed Web of Science ®Google Scholar
• Haji Ali Afzali H, Gray J, Beilby J, et al. A model-based economic evaluation of improved primary care management of patients with type 2 diabetes in Australia. Appl Health Econ Health Policy 2013;11:661-70
   PubMedGoogle Scholar
• van Haalen HG, Pompen M, Bergenheim K, et al. Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands. Clin Drug Investig 2014;34:135-46
   PubMed Web of Science ®Google Scholar
• Schaufler TM, Wolff M. Cost effectiveness of preventive screening programmes for type 2 diabetes mellitus in Germany. Appl Health Econ Health Policy 2010;8:191-202
   PubMedGoogle Scholar
• Li R, Zhang P, Barker LE, Hoerger TJ. Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes. Diabetes Care 2010;33:1193-9
   PubMed Web of Science ®Google Scholar
• Grima DT, Thompson MF, Sauriol L. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada. Pharmacoeconomics 2007;25:253-66
   PubMed Web of Science ®Google Scholar
• United Kingdom Prospective Diabetes Study (UKPDS) Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 1999;22:1125-36
   PubMed Web of Science ®Google Scholar
• Tsevat J, Goldman L, Soukup JR, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making 1993;13:161-5
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Lawrence W, Ghuschyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care 2005;43:736-49
   PubMed Web of Science ®Google Scholar
• Herman WH, Hoerger TJ, Brandle M, et al. Diabetes Prevention Program Research Group. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005;142:323-32
   PubMed Web of Science ®Google Scholar
• Zhou H, Isaman DJ, Messinger S, et al. A computer simulation model of diabetes progression, quality of life, and cost. Diabetes Care 2005;28:2856-63
   PubMed Web of Science ®Google Scholar
• Shin AY, Porter PJ, Wallace MC, Naglie G. Quality of life of stroke in younger individuals. Stroke 1997;28:2395-9
   PubMed Web of Science ®Google Scholar
• Huang ES, Brown SE, Ewigman BG, et al. Patient perceptions of quality of life with diabetes-related complications and treatments. Diabetes Care 2007;30:2478-83
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Ghushchyan V. Preference-based index scores for chronic conditions in the United States. Med Decis Making 2006;26:410
   PubMed Web of Science ®Google Scholar
• Wolf PA, D’Agostino RB, O’Neal MA, et al. Secular trends in stroke incidence and mortality. Stroke 1992;23:1551-5
   PubMed Web of Science ®Google Scholar
• Takeda A. [The policy for diabetes of local government]. Nippon Rinsho 2002;60(Suppl 10):608-12
   Google Scholar
• Sullivan PW, Slejko JF, Sculpher MJ, Ghushchyan V. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making 2011;31:800-4
   PubMed Web of Science ®Google Scholar
• Smith DW, Davies EW, Wissinger E, et al. A systematic literature review of cardiovascular event utilities. Expert Rev Pharmacoecon Outcomes Res 2013;13:767-90
   PubMed Web of Science ®Google Scholar
• Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995;274:1839-45
   PubMed Web of Science ®Google Scholar
• Lampe FC, Whincup PH, Wannamethee SG, et al. The natural history of prevalent ischaemic heart disease in middle-aged men. Eur Heart J 2000;21:1052-62
   PubMed Web of Science ®Google Scholar